Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer.

IF 1.6 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Open Medicine Pub Date : 2025-08-19 eCollection Date: 2025-01-01 DOI:10.1515/med-2025-1266

Mingyu Wang, Wenwen Zhang, Guangyan Cheng, Juan Xu, Pengpeng Qu

{"title":"Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer.","authors":"Mingyu Wang, Wenwen Zhang, Guangyan Cheng, Juan Xu, Pengpeng Qu","doi":"10.1515/med-2025-1266","DOIUrl":null,"url":null,"abstract":"Background: The exosomal microRNAs (exomiRNAs) are promising novel biomarkers for clinical detection and prognosis assessment of human cancers. The aim of this study was to identify potential exomiRNAs as biomarkers in ovarian cancer (OC).Methods: The candidate exomiRNAs were screened by analysis of GSE235525, GSE239685, and GSE216150 datasets and further validated in exosome samples from the serum of 61 patients with OC and OC cell lines by qPCR. The correlations between exomiRNAs expression and clinicopathological features of OC patients were assessed, and Kaplan-Meier survival and receiver operating characteristic curves were employed to analyze the prognostic and diagnostic values.Results: We found that exomiR-188-3p expression was downregulated in patients with OC and OC cell lines compared with healthy controls and normal cells. Decreased exomiR-188-3p was associated with advanced FIGO stage, lymph node metastasis, and distant metastasis. The area under the curve (AUC) values of exomiR-188-3p for differentiating OC, stage IA-IIA OC, and no metastatic OC from healthy controls were 0.8983, 0.8461, and 0.8179. And combination of exomiR-188-3p and CA125 yields better diagnostic efficacy, with AUC values of 0.9323, 0.8925, and 0.9120. Lower expression of exomiR-188-3p predicted a poor overall survival and progression-free survival in patients with OC.Conclusion: Decreased exomiR-188-3p could be a potential early diagnostic and prognostic biomarker for OC patients.","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251266"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413797/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2025-1266","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The exosomal microRNAs (exomiRNAs) are promising novel biomarkers for clinical detection and prognosis assessment of human cancers. The aim of this study was to identify potential exomiRNAs as biomarkers in ovarian cancer (OC).

Methods: The candidate exomiRNAs were screened by analysis of GSE235525, GSE239685, and GSE216150 datasets and further validated in exosome samples from the serum of 61 patients with OC and OC cell lines by qPCR. The correlations between exomiRNAs expression and clinicopathological features of OC patients were assessed, and Kaplan-Meier survival and receiver operating characteristic curves were employed to analyze the prognostic and diagnostic values.

Results: We found that exomiR-188-3p expression was downregulated in patients with OC and OC cell lines compared with healthy controls and normal cells. Decreased exomiR-188-3p was associated with advanced FIGO stage, lymph node metastasis, and distant metastasis. The area under the curve (AUC) values of exomiR-188-3p for differentiating OC, stage IA-IIA OC, and no metastatic OC from healthy controls were 0.8983, 0.8461, and 0.8179. And combination of exomiR-188-3p and CA125 yields better diagnostic efficacy, with AUC values of 0.9323, 0.8925, and 0.9120. Lower expression of exomiR-188-3p predicted a poor overall survival and progression-free survival in patients with OC.

Conclusion: Decreased exomiR-188-3p could be a potential early diagnostic and prognostic biomarker for OC patients.

Abstract Image

查看原文本刊更多论文

血清来源的exomiR-188-3p是一种很有前景的早期卵巢癌生物标志物。

背景：外泌体微小rna （exomiRNAs）是一种很有前景的新型生物标志物，可用于人类癌症的临床检测和预后评估。本研究的目的是鉴定卵巢癌（OC）中潜在的外显子rna作为生物标志物。方法：通过分析GSE235525、GSE239685和GSE216150数据集筛选候选exomirna，并通过qPCR在61例OC和OC细胞系患者血清外泌体样本中进一步验证。评估exomiRNAs表达与OC患者临床病理特征的相关性，并采用Kaplan-Meier生存和受试者工作特征曲线分析预后和诊断价值。结果：我们发现，与健康对照和正常细胞相比，exomiR-188-3p在OC患者和OC细胞系中的表达下调。exomiR-188-3p的减少与晚期FIGO分期、淋巴结转移和远处转移有关。exomiR-188-3p与健康对照区分OC、IA-IIA期OC和未转移OC的曲线下面积（AUC）值分别为0.8983、0.8461和0.8179。exomiR-188-3p与CA125联合诊断效果更好，AUC值分别为0.9323、0.8925、0.9120。exomiR-188-3p的低表达预示着OC患者较差的总生存期和无进展生存期。结论：降低的exomiR-188-3p可能是OC患者早期诊断和预后的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Medicine Medicine-General Medicine

CiteScore

3.00

自引率

0.00%

发文量

153

审稿时长

20 weeks

期刊介绍： Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.